Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
MedCity News3 天
Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity
The deal announced Wednesday calls for the companies to share in the development and commercialization of the Zealand drug, petrelintide. The partners will co-commercialize the drug in the U.S ...
Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...
STAT2 天
Roche partners with Zealand Pharma to push forward obesity drug
Roche partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion upfront, expanding its ...
Zacks.com on MSN2 天
RHHBY Enters Into a $5.3B Deal With Zealand Pharma for Obesity Drug
Roche RHHBY announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma for an ...
Roche pairs with Zealand Pharma on obesity drug candidate
Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to ...
Zealand Pharma, Roche have 2 best-in-class obesity assets, CEO tells Investing.com
Zealand Pharma shares surged more than 41% on Wednesday after announcing a $5.3 billion licensing deal with Roche for its GLP-1 obesity therapy petrelintide.
Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For ...
Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global ...
Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche
Zealand Pharma shares rose sharply after the Danish pharmaceutical company struck a licensing and collaboration deal of up to $5.3 billion with Roche. Shares in Zealand were up 25% at 609 Danish ...